NTRA ▼ -0.3% - Natera, Inc.
$NTRA Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
05-OCT-2026 08:03 AM ET
Share this post
More filings for $NTRA
NTRA ▼ -0.3% - Natera, Inc.Oct 5, 2026NTRA ▼ -0.2% - Natera, Inc.Sep 22, 2026NTRA ▼ -0.2% - Natera, Inc.Sep 22, 2026NTRA ▲ +0.4% - Natera, Inc.Sep 1, 2026NTRA ▼ -2.2% - Natera, Inc.Aug 28, 2026NTRA - Natera, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $NTRA filing history →💬 Comments
Loading comments…
Leave a comment